OPRX: Q3 Revenue Sets New Record, Up 202%

Zacks Small Cap Research

By Brian Marckx, CFA

Q3 2013 Pre-announcement:
  Revenue Up 202% yoy and 14% Ahead of Our Estimate...

Yesterday (10/8/13) OptimizeRx (OPRX) pre-announced expected revenue for the third quarter ending 9/30/13.  The company expects revenue of $1.37 million, which will be an increase of 202% from the same period in 2012 and is 14% better than our estimated $1.20 million.  The Q3 revenue number will also crush the previous quarterly record of $1.10 million, set in Q2 of this year.  The company also disclosed that there were almost 325k coupons distributed via SampleMD in the quarter, an increase of 22% from Q2 2013 and +260% from Q3 2012.

We have updated our model for the pre-announcement.  We now look for full-year 2013 revenue of $4.8 million (+133% yoy), up from $4.3 million prior to the announcement.  Our current year EPS estimate has moved from $0.04 to $0.05.  We have also made some slight upward adjustments to our out-year revenue estimates given the moderately steeper recent ramp in growth relative to our expectations.  We are maintaining our Outperform rating and $3.50/share price target. 

A copy of the latest research report can be downloaded here >> 
 OptimizeRx Report

Please visit 
SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning.

View Comments